Substance P Creates Pain Feedback Loop in Facial Pain by Activating Glial Cells Through RAS/RAF/MEK Pathway | Research

The takeaway

Substance P upregulates its own NK-1 receptor in satellite glial cells via the PKA/RAS-RAF-MEK-ERK pathway, creating a positive feedback loop that amplifies inflammatory orofacial pain.

Positive feedback
substance P upregulates its own receptor via RAS/RAF/MEK/ERK in glial cells, amplifying pain

What the researchers found

Substance P upregulated NK-1 receptor expression in trigeminal satellite glial cells via the PKA/RAS-B-RAF-MEK-ERK pathway. NK-1R antagonist, MEK inhibitor, RAF inhibitor, and PKA inhibitor all reduced NK-1 expression and pain behavior, while PKC inhibitor did not.

Why it matters

Understanding the molecular feedback loop that amplifies chronic facial pain could lead to more targeted treatments. Multiple points in this pathway (NK-1R, RAF, MEK, PKA) represent potential drug targets for conditions like trigeminal neuralgia and TMJ disorders.

The numbers in context

SP activated ERK1/2, PKA, PKC via NK1R; RAS/B-RAF-MEK-ERK pathway identified as key mediator of glial-mediated pain.

How the study worked

In vivo CFA-induced inflammatory orofacial pain model in rats. In vitro SGC cultures treated with substance P and pathway inhibitors. Pre-injection of inhibitors into trigeminal ganglion. qPCR, Western blot, and behavioral pain assessment.

Who was studied

Trigeminal ganglion satellite glial cells in orofacial pain model

What this study cannot tell us

Rat model of orofacial pain may not perfectly replicate human trigeminal pain conditions. In vitro SGC cultures may behave differently than in vivo. Some inhibitors used (e.g., sorafenib) have broad activity and clinical side effects.

How to read the evidence

Well-designed animal study with complementary in vivo and in vitro evidence and multiple pathway inhibitor controls confirming specificity.

When this study was published

Published in 2020. Glial cell involvement in pain amplification continues to be an active research area.

The bigger picture

Chronic pain is increasingly understood as involving glial cell activation, not just neuronal signaling. This substance P feedback loop in satellite glial cells provides a mechanistic target for breaking the pain amplification cycle that drives chronic orofacial conditions.

Questions still open

Could targeting the RAS/RAF/MEK pathway in glial cells specifically treat chronic facial pain?
Is this SP-NK-1R feedback loop also present in other chronic pain conditions?
Would combination therapy targeting multiple pathway nodes provide better pain relief?

Common questions

What is a positive feedback loop in pain?

In this case, substance P makes glial cells produce more of the receptor that substance P binds to, which means more substance P signaling, which produces even more receptors — a self-amplifying cycle that intensifies pain.

What are satellite glial cells?

Satellite glial cells surround nerve cell bodies in ganglia (nerve clusters). They were once thought to be passive support cells, but are now known to actively influence pain processing and can amplify or dampen pain signals.

Read the original research

Activation of the RAS/B-RAF-MEK-ERK pathway in satellite glial cells contributes to substance p-mediated orofacial pain.

The European journal of neuroscience, 51(11), 2205-2218

View on PubMed ↗Publisher’s paper ↗

Citation

Zhang, Yan-Yan; Song, Ning; Liu, Fei; Lin, Jiu; Liu, Meng-Ke; Huang, Chao-Lan; Liao, Da-Qing; Zhou, Cheng; Wang, Hang; Shen, Jie-Fei. (2020). Activation of the RAS/B-RAF-MEK-ERK pathway in satellite glial cells contributes to substance p-mediated orofacial pain.. The European journal of neuroscience, 51(11), 2205-2218. https://doi.org/10.1111/ejn.14619